Thursday, 20 Sep 2018

You are here

Opioid Marketing & Meals Tied to Opioid Prescribing

A current study in JAMA Internal Medicine showed that while US physicians who received no opioid-related marketing payments had fewer opioid prescriptions in 2015 compared with 2014, those receiving such payments wrote for more opioid in 2015.

Despite the increasing contribution of heroin and illicitly manufactured fentanyl to opioid-related overdose deaths in the United States, 40% of deaths involve prescription opioids.  While opioid prescribing has declined nationally, 2015 rate aer still three times higher than that seen in 1999.

Researchers reviewed physician payments from pharmaceutical companies in 2014 and linked these to prescribing patterns in 2014 and 2015. 

Of the 369,139 physicians studied, 7% received nonresearch opioid-related payments totaling $9, 071,976 in payments. Only 1.7% received >$1000 or total.  Marketing payments included speaking fees and/or honoraria, meals, travel, consulting fees, and education.

In multivariable modeling, receipt of any opioid-related payments from industry in 2014 was associated with 9.3% more opioid claims in 2015 compared with physicians who received no payments. Moreover, each industry meal was associated with an increase of 0.7% in opioid claims.

What a way to earn a meal.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA's Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Finalized

In response to the growing opioid crisis, the US Food and Drug Administration has approved the final Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), designed to reduce the risk of abuse, misuse, addiction, overdose, and deaths due to prescription opioid analgesics.

Lower Income Elderly are More Likely to Use Opioids

The Journal of Gerontology reports that the poorest of the elderly are the most likely to receive prescription opioids.

Unsafe Practices with Ambien Use

Ambien (zolpidem) is the most widely used prescription hypnotic sedative since its introduction in 1992 and is currently the fourth most frequently prescribed psychiatric drug (2013). Recent US Food and Drug Administration Drug Safety Communications suggest limitations on use to reduce adverse effects. A study of the Medical Expenditures Survey in 2015 revealed that over 3.8 million adults reported using one or more prescriptions for zolpidem.

Weight Loss Lessens Knee Pain in Obese

Obese knee osteoarthritis (OA) patients who lose > 20% of their weight were in significantly less pain, had better function and improved quality of life. 

Blacks Suffer When Pain is Poorly Defined

Racial discrimination was a key feature at a 2-day summit on pain management and the opioid crisis, hosted by the National Institutes of Health on Thursday and Friday.

Asheley Cockrell Skinner, PhD, of the Duke Clinical Research Institute in Durham, North Carolina, provided a broad overview of racial bias in opioid prescribing.